These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 32768938)

  • 21. Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study.
    Yang R; Liu H; Bai C; Wang Y; Zhang X; Guo R; Wu S; Wang J; Leung E; Chang H; Li P; Liu T; Wang Y
    Pharmacol Res; 2020 Jul; 157():104820. PubMed ID: 32360484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests.
    Wang F; Hou H; Wang T; Luo Y; Tang G; Wu S; Zhou H; Sun Z
    Travel Med Infect Dis; 2020; 36():101782. PubMed ID: 32526372
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Promising effects of tocilizumab in COVID-19: A non-controlled, prospective clinical trial.
    Dastan F; Saffaei A; Haseli S; Marjani M; Moniri A; Abtahian Z; Abedini A; Kiani A; Seifi S; Jammati H; Hashemian SMR; Pourabdollah Toutkaboni M; Eslaminejad A; Heshmatnia J; Sadeghi M; Nadji SA; Dastan A; Baghaei P; Varahram M; Yousefian S; Salamzadeh J; Tabarsi P
    Int Immunopharmacol; 2020 Nov; 88():106869. PubMed ID: 32889241
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dynamic changes in peripheral blood lymphocyte subsets in adult patients with COVID-19.
    Deng Z; Zhang M; Zhu T; Zhili N; Liu Z; Xiang R; Zhang W; Xu Y
    Int J Infect Dis; 2020 Sep; 98():353-358. PubMed ID: 32634585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of cellular immunity function and inflammatory factors assays in alveolar lavage fluid for severe COVID-19 pneumonia.
    Liao L; Yang GH
    J Med Virol; 2021 May; 93(5):2979-2987. PubMed ID: 33506950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing SARS-CoV-2 RNA levels and lymphocyte/T cell counts in COVID-19 patients revealed initial immune status as a major determinant of disease severity.
    Han M; Xu M; Zhang Y; Liu Z; Li S; He T; Li J; Gao Y; Liu W; Li T; Chen Z; Huang X; Cheng G; Wang J; Dittmer U; Witzke O; Zou G; Li X; Lu M; Zhang Z
    Med Microbiol Immunol; 2020 Dec; 209(6):657-668. PubMed ID: 32860073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: A structured summary of a study protocol for a randomised controlled trial.
    Li J; Zhang C; Wu Z; Wang G; Zhao H
    Trials; 2020 Jun; 21(1):488. PubMed ID: 32503657
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial.
    Sivapalan P; Ulrik CS; Bojesen RD; Lapperre TS; Eklöf JV; Håkansson KEJ; Browatzki A; Tidemansen C; Wilcke JT; Janner J; Gottlieb V; Meteran H; Porsbjerg C; Madsen BL; Moberg M; Pedersen L; Benfield TL; Lundgren JD; Knop FK; Biering-Sørensen T; Ghanizada M; Sonne TP; Bødtger UCS; Jensen SG; Rasmussen DB; Brøndum E; Tupper OD; Sørensen SW; Alstrup G; Laursen CB; Møller UW; Sverrild A; Jensen JS
    Trials; 2020 Jun; 21(1):513. PubMed ID: 32522282
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Suppressed T cell-mediated immunity in patients with COVID-19: A clinical retrospective study in Wuhan, China.
    Xu B; Fan CY; Wang AL; Zou YL; Yu YH; He C; Xia WG; Zhang JX; Miao Q
    J Infect; 2020 Jul; 81(1):e51-e60. PubMed ID: 32315725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of Risk Factors for 24 Patients With COVID-19 Developing From Moderate to Severe Condition.
    Li D; Liu C; Liu J; Hu J; Yang Y; Zhou Y
    Front Cell Infect Microbiol; 2020; 10():548582. PubMed ID: 33042873
    [No Abstract]   [Full Text] [Related]  

  • 32. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
    Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
    Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19).
    Huang YF; Bai C; He F; Xie Y; Zhou H
    Pharmacol Res; 2020 Aug; 158():104939. PubMed ID: 32445956
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Propolis and its potential against SARS-CoV-2 infection mechanisms and COVID-19 disease: Running title: Propolis against SARS-CoV-2 infection and COVID-19.
    Berretta AA; Silveira MAD; Cóndor Capcha JM; De Jong D
    Biomed Pharmacother; 2020 Nov; 131():110622. PubMed ID: 32890967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients.
    Wan S; Yi Q; Fan S; Lv J; Zhang X; Guo L; Lang C; Xiao Q; Xiao K; Yi Z; Qiang M; Xiang J; Zhang B; Chen Y; Gao C
    Br J Haematol; 2020 May; 189(3):428-437. PubMed ID: 32297671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune characteristics distinguish patients with severe disease associated with SARS-CoV-2.
    Li X; Liu Y; Li J; Sun L; Yang J; Xu F; Zhou J; Wan L; Xu X; Le A; Zhang W
    Immunol Res; 2020 Dec; 68(6):398-404. PubMed ID: 32989677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019].
    Wen L; Zhou Z; Jiang D; Huang K
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Apr; 32(4):426-429. PubMed ID: 32527346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical practice guidelines and experts' consensuses of traditional Chinese herbal medicine for novel coronavirus (COVID-19): protocol of a systematic review.
    Li Y; Li J; Zhong D; Zhang Y; Zhang Y; Guo Y; Clarke M; Jin R
    Syst Rev; 2020 Aug; 9(1):170. PubMed ID: 32746913
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of the clinical characteristics and early warning model construction of severe/critical coronavirus disease 2019 patients].
    Xu J; Zhao F; Han M; Ma L; Zhang T
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2020 Apr; 32(4):401-406. PubMed ID: 32527341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Broncho-alveolar inflammation in COVID-19 patients: a correlation with clinical outcome.
    Pandolfi L; Fossali T; Frangipane V; Bozzini S; Morosini M; D'Amato M; Lettieri S; Urtis M; Di Toro A; Saracino L; Percivalle E; Tomaselli S; Cavagna L; Cova E; Mojoli F; Bergomi P; Ottolina D; Lilleri D; Corsico AG; Arbustini E; Colombo R; Meloni F
    BMC Pulm Med; 2020 Nov; 20(1):301. PubMed ID: 33198751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.